Literature DB >> 17879211

Serum matrix metalloproteinases MMP-2 and MMP-9 and metalloproteinase tissue inhibitors TIMP-1 and TIMP-2 in diabetic nephropathy.

Jacek Rysz1, Maciej Banach, Robert A Stolarek, Jaroslaw Pasnik, Aleksandra Cialkowska-Rysz, Robert Koktysz, Mariusz Piechota, Zbigniew Baj.   

Abstract

BACKGROUND: The regulation of mesangial extracellular matrix (ECM) turnover engages a number of matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs). High glucose concentration affects ECM degradation and the activities of MMPs and TIMPs. ECM accumulation is involved in the pathogenesis of diabetic nephropathy.
METHODS: Serum MMP-9, MMP-2, TIMP-2 and TIMP-1 were measured with ELISA in patients with either chronic renal failure (CRF, n=20), type 2 diabetes mellitus (DM2, n=16) or diabetic nephropathy (DM2+CRF, n=14), and healthy controls (n=20).
RESULTS: Diabetic nephropathy was related with profound decrease of serum TIMP-2 (122.2 +/- 47.2 vs. 263.0 +/- 89.2 ng/mL), TIMP-1 (242.5 +/- 96.9 vs. 347.4 +/- 87.2 ng/mL) and MMP-2 (385.4 +/- 42.6 vs. 517.2 +/- 75.4 ng/mL) (p<0.001). Both TIMP-1 and TIMP-2 were reduced in diabetic nephropathy in comparison with either diabetes alone (p<0.01 and p<0.001; respectively) or CRF alone (p<0.001 for both). An approximately 2-fold increase of MMP-9/TIMP-1 and MMP-2/TIMP-2 ratio was found in diabetic nephropathy when compared with diabetes with normal renal function (p<0.01). Further, in DM2 patients, TIMP-2 was decreased when compared with CRF alone (219.2 +/- 71.8 vs. 296.8 +/- 58.4 ng/mL). MMP-2 was lowered in both groups of DM2 and CRF patients (413.8 +/- 59.0 ng/mL and 409.7 +/- 93.1 ng/mL, vs. normal control value of 517.2 +/- 75.4 ng/mL; p<0.001).
CONCLUSIONS: These data indicate that circulating TIMP-1, TIMP-2 and MMP-2 are decreased in patients with diabetic nephropathy when compared with either CRF or diabetes.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17879211

Source DB:  PubMed          Journal:  J Nephrol        ISSN: 1121-8428            Impact factor:   3.902


  41 in total

1.  Decreases in plasma MMP-2/TIMP-2 and MMP-9/TIMP-1 ratios in uremic patients during hemodialysis.

Authors:  Li-Che Lu; Chung-Wei Yang; Wen-Yeh Hsieh; Wan-Hsuan Chuang; Yi-Chang Lin; Chih-Sheng Lin
Journal:  Clin Exp Nephrol       Date:  2015-12-28       Impact factor: 2.801

Review 2.  Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors.

Authors:  Ralph A DeFronzo; W Brian Reeves; Alaa S Awad
Journal:  Nat Rev Nephrol       Date:  2021-02-05       Impact factor: 28.314

Review 3.  The role of Toll-like receptors in renal diseases.

Authors:  Anna Gluba; Maciej Banach; Simon Hannam; Dimitri P Mikhailidis; Agata Sakowicz; Jacek Rysz
Journal:  Nat Rev Nephrol       Date:  2010-02-23       Impact factor: 28.314

Review 4.  Matrix metalloproteinases and tissue inhibitors of metalloproteinases in chronic kidney disease and acute kidney injury: a systematic review of the literature.

Authors:  C L Sampieri; R A Orozco-Ortega
Journal:  Hippokratia       Date:  2018 Jul-Sep       Impact factor: 0.471

5.  Matrix metalloproteinase (MMP-2, -9) and tissue inhibitor (TIMP-1, -2) activity in tear samples of pediatric type 1 diabetic patients: MMPs in tear samples from type 1 diabetes.

Authors:  Chrysanthos Symeonidis; Eleni Papakonstantinou; Asimina Galli; Ioannis Tsinopoulos; Asimina Mataftsi; Spyridon Batzios; Stavros A Dimitrakos
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-12-20       Impact factor: 3.117

6.  Serum metalloproteinases MMP-2, MMP-9 and metalloproteinase tissue inhibitors TIMP-1 and TIMP-2 in patients on hemodialysis.

Authors:  Jacek Rysz; Maciej Banach; Robert A Stolarek; Dimitri P Mikhailidis; Aleksandra Cialkowska-Rysz; Lech Pokoca; Mariusz Piechota; Zbigniew Baj
Journal:  Int Urol Nephrol       Date:  2009-12-02       Impact factor: 2.370

7.  Homocysteine and Hypertension in Diabetes: Does PPARgamma Have a Regulatory Role?

Authors:  Utpal Sen; Suresh C Tyagi
Journal:  PPAR Res       Date:  2010-06-29       Impact factor: 4.964

8.  Ciglitazone, a PPARgamma agonist, ameliorates diabetic nephropathy in part through homocysteine clearance.

Authors:  Utpal Sen; Walter E Rodriguez; Neetu Tyagi; Munish Kumar; Soumi Kundu; Suresh C Tyagi
Journal:  Am J Physiol Endocrinol Metab       Date:  2008-09-09       Impact factor: 4.310

9.  Loss of TIMP3 enhances interstitial nephritis and fibrosis.

Authors:  Zamaneh Kassiri; Gavin Y Oudit; Vijay Kandalam; Ahmed Awad; Xiuhua Wang; Xiuhua Ziou; Nobuyo Maeda; Andrew M Herzenberg; James W Scholey
Journal:  J Am Soc Nephrol       Date:  2009-04-30       Impact factor: 10.121

10.  Evaluation of selected parameters of the antioxidative system in patients with type 2 diabetes in different periods of metabolic compensation.

Authors:  Jacek Rysz; Robert Błaszczak; Maciej Banach; Kornelia Kedziora-Kornatowska; Tomasz Kornatowski; Wojciech Tański; Józef Kedziora
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2007 Sep-Oct       Impact factor: 4.291

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.